Leishmaniasis, Visceral
9
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
LEISH-PED: Study on Leishmaniasis in Children
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)
Predicting Visceral Leishmaniasis in HIV Infected Patients
Evaluation of Antibody Detection Tests for Visceral Leishmaniasis Diagnosis in Eastern Africa
A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar
Combination Therapy in Indian Visceral Leishmaniasis
Clinical Investigation of Infections Due to Leishmanial Parasites